Bio-Techne Corporation (TECH)

Market Cap	13.26B
Revenue (ttm)	1.15B
Net Income (ttm)	203.00M
Shares Out	157.59M
EPS (ttm)	1.25
PE Ratio	67.32
Forward PE	42.41
Dividend	$0.32 (0.38%)
Ex-Dividend Date	May 10, 2024

Volume	894,921
Open	82.41
Previous Close	81.97
Day's Range	82.07 - 84.47
52-Week Range	51.79 - 89.91
Beta	1.23
Analysts	Strong Buy
Price Target	80.56 (-4.27%)
Earnings Date	May 1, 2024

About TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagn...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 9, 1989
• Employees: 3,050
• Stock Exchange: NASDAQ
• Ticker Symbol: TECH

Financial Performance

In 2023, Bio-Techne's revenue was $1.14 billion, an increase of 2.81% compared to the previous year's $1.11 billion. Earnings were $285.26 million, an increase of 4.86%.

Analyst Forecast

According to 10 analysts, the average rating for TECH stock is "Strong Buy." The 12-month stock price forecast is $80.56, which is a decrease of -4.27% from the latest price.

Price Target

$80.56

(-4.27% downside)

Analyst Consensus: Strong Buy